ArticleFrontiers in pediatrics2026
Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patent ductus arteriosus (PDA) results in pulmonary overcirculation and, depending on ductal size and patient age, may lead to symptoms of congestive heart failure and the development of pulmonary hypertension, among other complications. Percutaneous closure is currently considered the first-line option in most patients, depending on clinical and anatomical characteristics. Approved PDA occlusion devices are tailored to specific ductal morphologies; therefore, off-label devices such as muscular ventricular septal defect occluders, vascular plug II, or atrial septal defect occluders have been used in selected patients. With the advent of newer devices, and particularly the KONAR-MF™, a broad range of PDA morphologies can be treated, including in patients weighing <6 kg. Objectives: To evaluate the clinical and epidemiological characteristics of patients in whom PDA was closed using the off-label KONAR-MF™ device and to report outcomes at 6 months postprocedure. Method: This was a retrospective, single-center, descriptive observational case-series study with a 6-month follow-up. All patients who used the KONAR-MF™ device between 2024 and 2025 and met the inclusion and exclusion criteria were included in this study. Results: Seventeen patients were analyzed. The median age was 1 year and the median weight was 11 kg. Female sex accounted for 58.8% of cases. Functional class III was present in 58.8% of patients. Severe pneumonia was the reason for admission in 23.5% of patients. Down syndrome was recorded in 17.6% of patients. According to the Krichenko classification, 47.1% of PDAs were type C, and 11.7% were associated with a ventricular septal defect. The median minimum ductal diameter was 5 mm and the median ductal length was 8 mm. The median pulmonary artery pressure was 25 mmHg, median fluoroscopy time was 9.7 min, and median radiation dose was 46 mGy/cm Conclusion: Despite the small sample size of this study, the findings suggest that the KONAR-MF™ device, when used off-label, may be a valid alternative in complex anatomies or in underweight patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.